Mastering Cardiology for FNP Boards: The 4 High-Yield Concepts You Can't Ignore

Cardiology · 3 min read · September 9, 2026

Introduction

Cardiology is a heavy hitter on both the AANP and ANCC family nurse practitioner certification exams. When you open your exam booklet, you can guarantee you will face questions on heart murmurs, rhythm strips, heart failure management, and hypertension guidelines. Instead of feeling overwhelmed by the sheer volume of cardiac pathology, let's break down the core concepts that consistently show up on test day.

1. Decoding Heart Murmurs: Systolic vs. Diastolic

Murmur questions strike fear into the hearts of many NP students, but they become much easier when you categorize them systematically. Remember the golden rule: systolic murmurs occur between S1 and S2, while diastolic murmurs occur between S2 and S1.

Systolic Murmurs: The most common systolic murmurs include aortic stenosis and mitral regurgitation. Aortic stenosis is a harsh crescendo-decrescendo murmur heard best at the second right intercostal space that radiates to the neck. Mitral regurgitation is a holosystolic murmur heard best at the apex that radiates to the left axilla.
Diastolic Murmurs: These are always pathological on board exams. Examples include aortic regurgitation (high-pitched decrescendo murmur at the second left intercostal space) and mitral stenosis (an opening snap followed by a low-pitched diastolic rumble at the apex).

Board Tip: If a question describes a pregnant woman or a healthy young adult with a grade I or II soft systolic murmur that disappears with position changes, think innocent flow murmur. No workup is needed!

2. Heart Failure: Staging and Pharmacological Management

Heart failure management is a favorite topic for testing your understanding of current guidelines. You must clearly distinguish between Heart Failure with Reduced Ejection Fraction (HFrEF, EF $\le$ 40%) and Heart Failure with Preserved Ejection Fraction (HFpEF, EF $\ge$ 50%).

For HFrEF, the foundational medical therapy includes the 'fantastic four' that reduce mortality:

ARNI (angiotensin receptor-neprilysin inhibitor like sacubitril/valsartan) or ACE inhibitors/ARBs.
Beta-blockers (specifically evidence-based ones: carvedilol, metoprolol succinate, or bisoprolol).
MRA (mineralocorticoid receptor antagonists like spironolactone).
SGLT2 inhibitors (empagliflozin or dapagliflozin), which have revolutionized care for both diabetic and non-diabetic heart failure patients.

Clinical Pearl: Always check a patient's potassium and renal function within 1–2 weeks of starting or titrating an ACE inhibitor, ARB, or MRA to monitor for hyperkalemia and acute kidney injury.

3. Hypertension Guidelines and Compelling Indications

According to ACC/AHA guidelines, hypertension is diagnosed at $\ge$ 130/80 mmHg. Board questions rarely ask you to just diagnose stage 1 hypertension; instead, they test your ability to match a specific comorbidity with the right first-line antihypertensive medication.

Diabetes with proteinuria or Chronic Kidney Disease: ACE inhibitors or ARBs are first-line because they provide renal protection.
Post-Myocardial Infarction or Angina: Beta-blockers are the drug of choice to reduce myocardial oxygen demand and mortality.
Osteoporosis: Thiazide diuretics (like chlorthalidone or hydrochlorothiazide) are a great choice because they reduce calcium excretion in the urine and help preserve bone mineral density.

Board Tip: Never combine an ACE inhibitor with an ARB or a direct renin inhibitor. This dual blockade increases the risk of hyperkalemia, hypotension, and renal failure without providing extra clinical benefit.

4. Lipid Management and ASCVD Risk Estimation

Preventative cardiology is a major pillar of primary care. When evaluating a patient for statin therapy, you must consider whether they have clinical ASCVD, severe primary hypercholesterolemia (LDL $\ge$ 190 mg/dL), diabetes mellitus aged 40–75, or a calculated 10-year ASCVD risk score.

High-intensity statins (Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg) aim to lower LDL-C by $\ge$ 50% and are required for patients with clinical ASCVD or an LDL $\ge$ 190.
Moderate-intensity statins (Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg, Simvastatin 20–40 mg) aim for a 30% to 49% reduction in LDL-C.

You've got this! Cardiology doesn't have to be your weak spot. By focusing on high-yield presentation patterns, guidelines, and medication safety, you are setting yourself up for total success on exam day. Head over to The FNP Review for more board prep resources to help you pass with flying colors.